Search Result

Results for "

radioligand

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adenosine Receptor (1) Adrenergic Receptor (6) Amyloid-β (1) Cannabinoid Receptor (2) Cholecystokinin Receptor (1) Cholinesterase (ChE) (2) Dopamine Receptor (1) Drug-Linker Conjugates for ADC (1) iGluR (1) Isotope-Labeled Compounds (5) LPL Receptor (3) LRRK2 (1) mAChR (1) Neuropeptide Y Receptor (2) Orexin Receptor (OX Receptor) (1) Prostaglandin Receptor (1) PSMA (1) Serotonin Transporter (1) Sigma Receptor (1) Sodium Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (18)

By Targets:

5-HT Receptor (3)

Adenosine Receptor (1)

Adrenergic Receptor (6)

Amyloid-β (1)

Cannabinoid Receptor (2)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (2)

Dopamine Receptor (1)

Drug-Linker Conjugates for ADC (1)

iGluR (1)

Isotope-Labeled Compounds (5)

LPL Receptor (3)

LRRK2 (1)

mAChR (1)

Neuropeptide Y Receptor (2)

Orexin Receptor (OX Receptor) (1)

Prostaglandin Receptor (1)

PSMA (1)

Serotonin Transporter (1)

Sigma Receptor (1)

Sodium Channel (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (3)

Endocrinology (1)

Inflammation/Immunology (2)

Metabolic Disease (5)

Neurological Disease (18)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113938

AZD4694 NAV4694	Amyloid-β	Cardiovascular Disease
AZD4694 (NAV4694), a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for Aβ fibrils (K_d = 2.3 nM) .

HY-100346

PK14105

Others Others

PK14105 is a biological evaluation as a potential radioligand for PET studies of PBBS receptors.

PK14105	Others	Others
PK14105 is a biological evaluation as a potential radioligand for PET studies of PBBS receptors.

HY-156124

*Sigma-2 Radioligand* 1**	Sigma Receptor	Cancer
Sigma-2 Radioligand 1 (compound 1) is a Sigma-2 selective ligand. Sigma-2 Radioligand 1 has good biodistribution in mice and good in vivo activity in rats. [18F] Modified Sigma-2 Radioligand 1 for visualization of tumors in micro-PET/CT imaging, exhibiting high tumor uptake and tumor-to-background ratio. Experiments show that Sigma-2 Radioligand 1 binds highly specifically in U87MG glioma xenografts .

HY-149210

*S1PR1 Radioligand* 1**	LPL Receptor	Others
S1PR1 Radioligand 1(compound 6 h) is a specific S1PR1 radioligand with IC₅₀ = 8.7 nM. S1PR1 Radioligand 1 has good brain uptake and can be used as a S1PR1-specific F-18 radiotracer for studying the function of S1PR1 in brain diseases .

HY-155741

*CB2 PET Radioligand* 1**	Cannabinoid Receptor	Neurological Disease
CB2 PET Radioligand 1 (compound [18F]9) is a PET Radioligand targeting to hCB2 (Ki=7.7 nM). CB2 PET Radioligand 1 is prepared with Cu-mediated 18F-fluorination. CB2 PET Radioligand 1 shows high brain uptake in a murine model of neuroinflammation .

HY-108972

SQ 29548

Prostaglandin Receptor Metabolic Disease

SQ 29548, a high affinity radioligand, is a selective thromboxane-prostanoid (TP) receptor antagonist .
HY-141804

ER176

Others Neurological Disease

ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .
HY-136873

UCB-J

Others Others

UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .
HY-141536

PSMA-ALB-56

Drug-Linker Conjugates for ADC Cancer

PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder .

SQ 29548	Prostaglandin Receptor	Metabolic Disease
SQ 29548, a high affinity radioligand, is a selective thromboxane-prostanoid (TP) receptor antagonist .

ER176	Others	Neurological Disease
ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

UCB-J	Others	Others
UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .

PSMA-ALB-56	Drug-Linker Conjugates for ADC	Cancer
PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder .

HY-14121

MRS 1754 3 Publications Verification	Adenosine Receptor	Metabolic Disease Inflammation/Immunology
MRS 1754 is a selective antagonist radioligand for A_2B adenosine receptor with very low affinity for A₁ and A₃ receptors of both humans and rats .

HY-B1486

Oxprenolol hydrochloride 1 Publications Verification Ba 39089
Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-B1486A

Oxprenolol Ba 39089 free base
Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-153432

TRV-7019	Cholinesterase (ChE)	Neurological Disease
TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity .

HY-103326

NIDA-41020	Cannabinoid Receptor	Neurological Disease
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .

HY-110223

Atomoxetine-d3 hydrochloride	Adrenergic Receptor	Neurological Disease
Atomoxetine-d3 hydrochloride is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-17385S

Atomoxetine-d5 hydrochloride Tomoxetine-d₅ hydrochloride; LY 139603-d₅; (R)-Tomoxetine-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1][2].

HY-149869

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

HY-118836

GSK215083	5-HT Receptor	Others
GSK215083 is a high affinity 5-HT6 receptor antagonist. GSK215083 can serves as a promising 5-HT6 radioligand candidate by radiolabeled with (11)C via methylation .

HY-103139

Altanserin hydrochloride	Others	Metabolic Disease
Altanserin is a 5-hydroxytryptamine (5-HT_2A) selective radioligand. Altanserin delivers human serotonin. Altanserin can be used to study the biochemical and cellular mechanisms of vulnerability to extracellular 5-HT increase .

HY-B1486S

Oxprenolol-d7 hydrochloride Ba 39089-d₇	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-B1486AS

Oxprenolol-d7	Isotope-Labeled Compounds Adrenergic Receptor
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-103141

SB-258585 hydrochloride	Others	Neurological Disease
SB-258585 is a high affinity ligand for the 5-HT₆ receptor. SB-258585 binds highly to a single receptor population in a human cell line that recombines 5-HT₆ receptors. SB-258585 can be used to label recombinant and natural 5-HT₆ receptor .

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride (Rac)-Tomoxetine d₇ (hydrochloride); (Rac)-LY 139603 d₇	Serotonin Transporter Sodium Channel Isotope-Labeled Compounds	Neurological Disease
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1].

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-118424

JNJ-55511118	iGluR	Neurological Disease
JNJ-55511118 is a highly potent, reversible, and selective AMPA receptor inhibitor selective for TARP-γ8. JNJ-55511118 fully displaces the radioligand (20 nM) with the K_i of 26 nM in competition binding experiments. JNJ-55511118 is a tool molecule with potential therapeutic utility as an anticonvulsant or neuroprotectant .

HY-161246

uPSEM792	Others	Neurological Disease
uPSEM792 is a pharmacologically selective effector molecules (PSEM) agonist for PSAM ⁴-GlyR, with an affinity of K_i of 0.7 nM. uPSEM792 is a substrate for efflux transporters in brains of wild type and dual P-gp and BCRP knockout mice. uPSEM7952 is a possible lead for developing the PET radioligand for PSAM ⁴-GlyR .

HY-133116

4-Hydroxyatomoxetine	Adrenergic Receptor	Neurological Disease
4-Hydroxyatomoxetine is an active metabolite of Atomoxetine. 4-Hydroxyatomoxetine is metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-147366

*RBP4 ligand-1*	Others	Metabolic Disease
RBP4 ligand-1 is a non-retinoid ligands for (RBP4) retinol-binding protein 4. The hRBP4_SPA IC₅₀ and RBP4–TTR FRET IC₅₀ values are 0.23±0.11 and 0.13±0.12 μM in the radioligand binding assay and FRET assay, respectively .

HY-122537A

Arotinolol	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-116020

FAUC 365	Dopamine Receptor	Neurological Disease
FAUC 365 is a highly dopamine D3 receptor-selective antagonist with K_i values of 0.5 nM, 340, 2600, and 3600 nM at D3, D4.4, D2_short, and D2_Long receptors, respectively. FAUC 365 can be used for the research of schizophrenia, and Parkinson's disease .

HY-10569

Ponesimod 2 Publications Verification ACT-128800	LPL Receptor	Inflammation/Immunology
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-103151

CP94253 hydrochloride	5-HT Receptor	Neurological Disease
CP94253 hydrochloride is a potent and selective agonist of 5-HT_1B receptor (K_i= 2 nM in a radioligand binding assay).K_i values for 5-HT_1A, 5-HT_1D, 5-HT_1C and 5-HT₂ receptors are 89, 49, 860, and 1600 nM respectively . CP94253 hydrochloride is centrally active upon systemic administration in vivo .

HY-10569S

Ponesimod-d4 ACT-128800-d₄	Isotope-Labeled Compounds LPL Receptor	Others
Ponesimod-d₄ (ACT-128800-d₄)is the deuterium labeledPonesimod(HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-122203

PCS1055 dihydrochloride	mAChR Cholinesterase (ChE)	Neurological Disease
PCS1055 dihydrochloride is a potent, selective and competitive muscarinic M4 receptor antagonist with an IC₅₀ of 18.1 nM and a K_d of 5.72 nM. PCS1055 dihydrochloride inhibits radioligand [ ³H]-NMS binding to the M4 receptor with a K_i of 6.5 nM. PCS1055 dihydrochloride exhibits >100-fold selectivity over M1-, M3-, and M5-receptors and 30-fold selectivity at the M2 receptor. PCS1055 dihydrochloride is also a potent AChE inhibitor with IC₅₀ s of 22 nM and 120 nM for electric eel and human AChE, respectively .

HY-10569S1

Ponesimod-d7 ACT-128800-d₇	Isotope-Labeled Compounds	Others
Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-10898

SB-674042 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-674042 is a potent and selective non-peptide orexin OX₁ receptor antagonist (K_d=5.03 nM), exhibits 100-fold selectivity for OX₁ over OX₂ receptors with IC₅₀ values of 3.76 nM and 531 nM, respectively .

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

Cat. No.	Product Name	Chemical Structure

HY-B1486S

Oxprenolol-d7 hydrochloride
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-17385S

Atomoxetine-d5 hydrochloride
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1][2].

HY-B1486AS

Oxprenolol-d7
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1].

HY-10569S

Ponesimod-d4
Ponesimod-d₄ (ACT-128800-d₄)is the deuterium labeledPonesimod(HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-10569S1

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: